CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual MeetingGlobeNewsWire • 11/03/22
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/01/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and TherapyGlobeNewsWire • 09/29/22
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)GlobeNewsWire • 09/28/22
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR DrugInvestors Business Daily • 09/27/22
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022Business Wire • 09/27/22
Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapyMarket Watch • 09/16/22